STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer - A Multi-Arm Multi-Stage Randomised Controlled Trial

Clinical Oncology

Volumn 20, Issue 8, 2008, Pages 577-581

  James, N D ^a   Sydes, M R ^b   Clarke, N W ^c   Mason, M D ^d   Dearnaley, D P ^e   Anderson, J ^f   Popert, R J ^g   Sanders, K ^b   Morgan, R C ^b   Stansfeld, J ^h   Dwyer, J ^h   Masters, J ⁱ   Parmar, M K B ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b MRC CLINICAL TRIALS UNIT   (United Kingdom)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d CARDIFF UNIVERSITY   (United Kingdom)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^f ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^g GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^h Urology Research Department   (United Kingdom)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BISPHOSPHONIC ACID DERIVATIVE; CELECOXIB; CLODRONIC ACID; CYCLOOXYGENASE 2 INHIBITOR; DOCETAXEL; EPIRUBICIN; MITOXANTRONE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTATE SPECIFIC ANTIGEN; ROFECOXIB; TAXANE DERIVATIVE; ZOLEDRONIC ACID;

ADJUVANT THERAPY; BONE METASTASIS; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER INVASION; CANCER PREVENTION; CANCER RECURRENCE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG POTENTIATION; DRUG SAFETY; EDITORIAL; HIGH RISK PATIENT; HUMAN; LIVER DYSFUNCTION; MONOTHERAPY; OVERALL SURVIVAL; PATIENT PARTICIPATION; PRIORITY JOURNAL; PROSTATE CANCER; RISK REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIPHOSPHONATES; HUMANS; IMIDAZOLES; MALE; NEOPLASM METASTASIS; PILOT PROJECTS; PROSTATIC NEOPLASMS; PYRAZOLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONAMIDES; TAXOIDS;

EID: 51449097507     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2008.07.002     Document Type: Editorial

References (32)

1. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 15 (2004) 1502-1512
2. Petrylak D.P., Tangen C.M., Hussain Mh M.E., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 15 (2004) 1513-1520
3. Berthold D.R., Pond G.R., Soban F., de Wit R., Eisenberger M., and Tannock I.F. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26 2 (2008 Jan 10) 242-245
4. Berthold D.R., Pond G.R., Roessner M., de Wit R., Eisenberger M., and Tannock A.I. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res 14 9 (2008 May 1) 2763-2767
5. Wang J., Halford S., Rigg A., Roylance R., Lynch M., and Waxman J. Adjuvant mitozantrone chemotherapy in advanced prostate cancer. BJU Int 86 6 (2000) 675-680
6. Pummer K., Lehnert M., Stettner H., and Hubmer G. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Eur Urol 32 Suppl 3 (1997) 81-85
7. Dearnaley D.P., Sydes M.R., Mason M.D., et al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 trial). J Natl Cancer Inst 95 17 (2003) 1300-1311
8. Mason M.D., Sydes M.R., Glaholm J., et al. Oral sodium clodronate for nonmetastatic prostate cancer-results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873). J Natl Cancer Inst 99 10 (2007 May 16) 765-776
9. Saad F., Gleason D.M., Murray R., et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94 19 (2002) 1458-1468
10. Saad F., Gleason D.M., Murray R., et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96 11 (2004) 879-882
11. Prostate cancer: diagnosis and treatment. In: Cancer NCCf, editor. National Collaborating Centre for Cancer (2nd Floor, Front Suite, Park House, Greyfriars Road, Cardiff, CF10 3AF) at Velindre NHS Trust, Cardiff, Wales; 2008.
12. SMC Advice Zoledronic acid. In: Scotland N, editor. 2004.
13. Boissier S., Ferreras M., Peyruchaud O., et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 60 11 (2000) 2949-2954
14. Boissier S., Magnetto S., Frappart L., et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 57 18 (1997) 3890-3894
15. Fournier P., Boissier S., Filleur S., et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62 22 (2002) 6538-6544
16. Magnetto S., Boissier S., Delmas P.D., and Clezardin P. Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int J Cancer 83 2 (1999) 263-269
17. Montague R., Hart C.A., George N.J., Ramani V.A., Brown M.D., and Clarke N.W. Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of Zoledronic acid in prostate cancer. Eur Urol 46 3 (2004 Sep) 389-401 [discussion 401-402]
18. Norrish A.E., Jackson R.T., and McRae C.U. Non-steroidal anti-inflammatory drugs and prostate cancer progression. Inte J Cancer 77 4 (1998) 511-515
19. Nelson J.E., and Harris R.E. Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncol Rep 7 1 (2000) 169-170
20. Roberts R.O., Jacobson D.J., Girman C.J., Rhodes T., Lieber M.M., and Jacobsen S.J. A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. [see comments.]. Mayo Clin Proc 77 3 (2002) 219-225
21. Khor L.Y., Bae K., Pollack A., et al. COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. Lancet Oncol 8 10 (2007 Oct) 912-920
22. James N. Cyclooxygenase-2 inhibitors and prostate cancer. Lancet Oncol 8 10 (2007 Oct) 859-860
23. Brubaker K.D., Brown L.G., Vessella R.L., and Corey E. Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment. BMC Cancer 6 (2006) 15
24. Witters L.M., Crispino J., Fraterrigo T., Green J., and Lipton A. Effect of the combination of docetaxel, zoledronic acid, and a COX-2 inhibitor on the growth of human breast cancer cell lines. Am J Clin Oncol 26 4 (2003) S92-SS7
25. Parmar MKB, Barthel FMS, Sydes MR, et al. Speeding up the evaluation of new agents in cancer. J Natl Cancer Inst. doi: 10.1093/jnci/djn267.
26. Bookman M.A. GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with Gemcitabine (G), PEG-liposomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. Am Soc Clin Oncol (2006) p. 5002
27. Seymour M.T., Maughan T.S., Ledermann J.A., et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 370 9582 (2007 Jul 14) 143-152
28. Crawford E.D., Eisenberger M.A., McLeod D.G., et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321 7 (1989) 419-424
29. Eisenberger M.A., Blumenstein B.A., Crawford E.D., et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339 15 (1998) 1036-1042
30. Eisenberger M.A., Crawford E.D., Wolf M., et al. Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). The National Cancer Institute Intergroup Study #0036. Semin Oncol 21 5 (1994) 613-619
31. Oefelein M.G., Agarwal P.K., and Resnick M.I. Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era. J Urol 171 4 (2004 Apr) 1525-1528
32. Sharifi N., Dahut W.L., Steinberg S.M., et al. A retrospective study of the time to clinical endpoints for advanced prostate cancer. BJU Int 96 7 (2005 Nov) 985-989